JNJ Stock Overvalued by 37.4%, Despite Strong Dividend Fundamentals

Johnson & Johnson (NYSE: JNJ) announced on September 14, 2026 that its Phase 3 PAPILLON trial evaluating Rybrevant combined with chemotherapy in advanced non-small cell lung cancer patients has reached a significant milestone. The final overall survival results showed that the combination therapy extended median overall survival to nearly three years in patients harboring specific genetic mutations, surpassing the 27.9 months median survival observed with chemotherapy alone.

The company's dividend profile remains attractive for income-focused investors, with a current yield of 1.99% and a payout ratio of 50%. However, the stock's valuation presents a cautionary note, as it is trading at $265.58, which is approximately 37.4% above its intrinsic value estimate of $193.33.

JNJ's strong dividend fundamentals are driven by a conservative payout ratio and consistent dividend growth, averaging 4.9% annually over the past three years. However, insider activity reveals notable net selling over the past 12 months, with insiders offloading $154.9 million in shares versus only $0.3 million purchased.